Lauren Harshman

About Lauren Harshman

• Immunotherapy has come of age with the approval of Sipuleucel-T (Provenge) and the introduction of ipilimumab (Yervoy) and other similar immune modulators into clinical trials for advanced metastatic prostate cancer.
• Dr. Harshman will study the biologic activities of a genetically-modified prostate tumor cell vaccine in the setting of Xtandi (enzalutamide) therapy for advanced, metastatic prostate cancer.
• These translational investigations, while developing a new therapy for patients, will also result in a biological understanding of the mechanisms of sensitivity and resistance to immunotherapy for prostate cancer. What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.

What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.